76 related articles for article (PubMed ID: 31394651)
1. Proteomic Analysis of a Human Prostate Cancer Cell Line after Incubation with a Novel Somatostatin14 Derivative.
Liu Z; Mrquez M; Nilsson S; Holmberg AR; Alaiya A
Cancer Genomics Proteomics; 2005; 2(6):347-352. PubMed ID: 31394651
[TBL] [Abstract][Full Text] [Related]
2. Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2009 Dec; 22(6):1451-8. PubMed ID: 19885599
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin effects on the proteome of the LNCaP cell-line.
Liu Z; Bengtsson S; Krogh M; Marquez M; Nilsson S; James P; Aliaya A; Holmberg AR
Int J Oncol; 2007 May; 30(5):1173-9. PubMed ID: 17390019
[TBL] [Abstract][Full Text] [Related]
4. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
5. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
6. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin Derivate (smsDX) Attenuates the TAM-Stimulated Proliferation, Migration and Invasion of Prostate Cancer via NF-κB Regulation.
Guo Z; Xing Z; Cheng X; Fang Z; Jiang C; Su J; Zhou Z; Xu Z; Holmberg A; Nilsson S; Liu Z
PLoS One; 2015; 10(5):e0124292. PubMed ID: 26010447
[TBL] [Abstract][Full Text] [Related]
8. A novel somatostatin conjugate with a high affinity to all five somatostatin receptor subtypes.
Wulbrand U; Feldman M; Pfestroff A; Fehman HC; Du J; Hiltunen J; Marquez M; Arnold R; Westlin JE; Nilsson S; Holmberg AR
Cancer; 2002 Feb; 94(4 Suppl):1293-7. PubMed ID: 11877759
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer.
Joensuu TK; Nilsson S; Holmberg AR; Márquez M; Tenhunen M; Saarto T; Joensuu H
Ann N Y Acad Sci; 2004 Dec; 1028():361-74. PubMed ID: 15650261
[TBL] [Abstract][Full Text] [Related]
11. Proteomic-based identification of multiple pathways underlying n-butylidenephthalide-induced apoptosis in LNCaP human prostate cancer cells.
Pang CY; Chiu SC; Harn HJ; Zhai WJ; Lin SZ; Yang HH
Food Chem Toxicol; 2013 Sep; 59():281-8. PubMed ID: 23770345
[TBL] [Abstract][Full Text] [Related]
12. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
[TBL] [Abstract][Full Text] [Related]
13. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
14. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1.
Fu X; Ravindranath L; Tran N; Petrovics G; Srivastava S
DNA Cell Biol; 2006 Mar; 25(3):135-41. PubMed ID: 16569192
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
16. Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis.
Sieh S; Taubenberger AV; Lehman ML; Clements JA; Nelson CC; Hutmacher DW
Bone; 2014 Jun; 63():121-31. PubMed ID: 24530694
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
[TBL] [Abstract][Full Text] [Related]
18. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action.
Brevini TA; Bianchi R; Motta M
J Clin Endocrinol Metab; 1993 Sep; 77(3):626-31. PubMed ID: 7690358
[TBL] [Abstract][Full Text] [Related]
19. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.
Qiu JX; Zhou ZW; He ZX; Zhao RJ; Zhang X; Yang L; Zhou SF; Mao ZF
Drug Des Devel Ther; 2015; 9():349-417. PubMed ID: 25609920
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
